The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review

Recurrence of FSGS occurs in 30–40% of allografts. Therapies for recurrence are not well established. We retrieved all published reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab, to determine factors associated with trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Araya, Carlos E., Dharnidharka, Vikas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235904/
https://www.ncbi.nlm.nih.gov/pubmed/22174985
http://dx.doi.org/10.1155/2011/374213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235904/
https://www.ncbi.nlm.nih.gov/pubmed/22174985
http://dx.doi.org/10.1155/2011/374213

Ejemplares similares